Department of Parasitology, Mycology, Dermatology, EA 7380 UPEC Dynamyc, Ecole nationale vétérinaire d'Alfort, F-94700, Maisons-Alfort, France.
ADVETIA Veterinary Hospital center, 9 Avenue Louis Breguet, 78140, Vélizy-Villacoublay, France.
BMC Vet Res. 2019 Oct 11;15(1):337. doi: 10.1186/s12917-019-2081-8.
Flea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats. This was an open pre-treatment versus post-treatment clinical field study. All cats included in the study presented pruritus, skin lesions or other evidence compatible with flea infestation. Skin lesions were assessed (using SCORFAD) at days 0, 28, 56 and 84 whereas pruritus severity was assessed (using PVAS) at days 0, 15, 28, 56 and 84. On day 0, The fluralaner (280 mg/ml) product (Bravecto® spot-on for cats) was supplied in pipettes containing 0.4, 0.89 and 1.79 ml for cats of 1.2-2.8 kg, > 2.8-6.25 kg and > 6.25-12.5 kg body weight, respectively. The other animals living in the same household also received fluralaner. Based on cytological examination at day 0, oral amoxicillin and clavulanic acid was prescribed for 21 days if indicated. For cats presenting intense pruritus and discomfort at day 0, oral prednisolone at 0.5 mg/kg was prescribed for 3 days.
During the study all cats, except for one (cat number 10), improved significantly. Post-treatment median SCORFAD scores at all evaluations were significantly different from the pre-treatment score on day 0 (P values < 0.002 for all three post treatment examination days) with a score reduction of 49% on day 28, 79% on day 56 and 87% on day 84. The PVAS score decreased significantly over the study period for all cats but one (cat number 10). Post-treatment median PVAS scores at all evaluations were significantly different from the pre-treatment PVAS score on day 0 (P value < 0.002 for all four post-treatment days) with a reduction of 46% on day 15, 67% on day 28, 82% on day 56 and 92% on day 84. No adverse reaction or other health issue was reported during the study.
A single topical treatment with fluralaner results in a significant reduction of flea bite allergic dermatitis clinical signs in cats over the subsequent 12 weeks without any additional environmental treatment.
跳蚤叮咬被认为是猫过敏性皮炎的主要原因。需要能够控制与跳蚤叮咬相关的猫过敏性皮炎的临床症状的治疗方法。这是一项开放的治疗前与治疗后临床现场研究。所有纳入研究的猫均表现出瘙痒、皮肤病变或其他与跳蚤感染相符的证据。皮肤病变(使用 SCORFAD)在第 0、28、56 和 84 天进行评估,而瘙痒严重程度(使用 PVAS)在第 0、15、28、56 和 84 天进行评估。第 0 天,氟雷拉纳(280mg/ml)产品(Bravecto®猫用滴剂)以 0.4、0.89 和 1.79ml 的剂量提供给体重为 1.2-2.8kg、>2.8-6.25kg 和>6.25-12.5kg 的猫。同一家庭中饲养的其他动物也接受了氟雷拉纳。基于第 0 天的细胞学检查,如果需要,开处方口服阿莫西林克拉维酸 21 天。对于第 0 天瘙痒严重和不适的猫,开处方口服泼尼松龙 0.5mg/kg,连续 3 天。
在研究期间,除了一只猫(10 号猫)外,所有猫的病情均明显改善。所有评估的治疗后中位数 SCORFAD 评分与第 0 天的治疗前评分相比均有显著差异(所有三个治疗后评估日的 P 值均<0.002),第 28 天、第 56 天和第 84 天的评分分别降低了 49%、79%和 87%。所有猫(10 号猫除外)的 PVAS 评分在研究期间均显著下降。所有治疗后评估的 PVAS 评分与第 0 天的治疗前 PVAS 评分相比均有显著差异(所有四个治疗后评估日的 P 值均<0.002),第 15 天、第 28 天、第 56 天和第 84 天的评分分别降低了 46%、67%、82%和 92%。研究期间未报告任何不良反应或其他健康问题。
单次局部应用氟雷拉纳可显著减轻猫在随后的 12 周内因跳蚤叮咬引起的过敏性皮炎的临床症状,无需额外的环境治疗。